ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies
Two collaborative projects with public research centers with a global budget of 2.3 million euros.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the granting, through a provisional resolution proposal, of two aids within the Spanish research plan 2021-2023 for public-private collaboration projects: the DICTIONIS Project with a budget of 951,000 euros (€) and the MODERN Project with a budget of €1,328,594. The plan is funded by the Spanish State Research Agency and the Ministry of Science and Innovation within the framework of the recovery, transformation and resilience plan financed by the European Union (NextGenerationEU).
The DICTIONIS Project will be carried out in collaboration with the Fundació Centre de Regulació Genomica from Barcelona (Spain) and focuses on the diagnosis of chromatinopathies by detecting alterations in histone modifications.
The MODERN Project will be carried out in collaboration with the Universitat Autònoma de Barcelona, the Fundació de Institut d'Investigació Biomédica de Bellvitge (IDIBELL) and LEiTAT and focuses on high-throughput technologies for the discovery and validation of new epigenetic targets and inhibitors for the treatment of neuronal pathologies.
Both projects started on April 1, 2023 and will have a duration of two years. The projects have an overall budget of €2.3 million euros, of which Oryzon will receive approximately a €1.35 million aid and an additional grant to hire two Ph.D.s.
Dr. Jordi Xaus, Oryzon’s Chief Scientific Officer, said: "We thank the Spanish Ministry of Science for these aids that underline the scientific relevance of our research in the epigenetic area in neurological diseases, as well as to reinforce efficiencies and multiply efforts with the national network of public research institutions. These programs are a continuation and complement to our vafidemstat program, which is already in Phase 2 in two highly prevalent psychiatric diseases, borderline personality disorder and schizophrenia, and reinforce the company's leadership in the development of innovative drugs against epigenetic targets useful in the treatment of neurological pathologies, a field of great medical need and with an important commercial opportunity".